RFG Advisory LLC Trims Position in Masimo Corporation $MASI

Key Points

• RFG Advisory LLC reduced its stake in Masimo Corporation by 42.7%, owning 3,887 shares after selling 2,893 during the second quarter, reflecting a current value of approximately $654,000.
• Masimo shares have seen varied ratings, with Wall Street analysts giving one "Strong Buy", five "Buy", one "Hold", and one "Sell", alongside a consensus price target of $194.60.
• Masimo's stock is currently priced at $146.78, down 0.3%, and has experienced a 52-week low of $133.70 and a high of $194.88.

RFG Advisory LLC lessened its stake in Masimo Corporation (NASDAQ:MASI - Free Report) by 42.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,887 shares of the medical equipment provider's stock after selling 2,893 shares during the period. RFG Advisory LLC's holdings in Masimo were worth $654,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Twin Tree Management LP purchased a new position in Masimo in the 1st quarter worth about $29,000. Farther Finance Advisors LLC increased its stake in Masimo by 128.9% in the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock worth $35,000 after buying an additional 116 shares during the period. Hilltop National Bank purchased a new position in Masimo in the 2nd quarter worth about $37,000. Anderson Financial Strategies LLC purchased a new position in Masimo in the 1st quarter worth about $49,000. Finally, Quarry LP increased its stake in Masimo by 253.5% in the 1st quarter. Quarry LP now owns 449 shares of the medical equipment provider's stock worth $75,000 after buying an additional 322 shares during the period. Hedge funds and other institutional investors own 85.96% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on MASI shares. Wall Street Zen raised shares of Masimo from a "hold" rating to a "buy" rating in a research note on Tuesday. Weiss Ratings reiterated a "sell (d)" rating on shares of Masimo in a research note on Wednesday, October 8th. Zacks Research raised shares of Masimo from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 3rd. BTIG Research reissued a "buy" rating and set a $198.00 price objective on shares of Masimo in a report on Thursday, September 11th. Finally, Piper Sandler lifted their price objective on shares of Masimo from $200.00 to $210.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $194.60.

Masimo Stock Down 0.3%

NASDAQ:MASI opened at $146.78 on Friday. Masimo Corporation has a fifty-two week low of $133.70 and a fifty-two week high of $194.88. The stock has a market capitalization of $7.97 billion, a P/E ratio of -17.23 and a beta of 1.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. The company's 50-day simple moving average is $145.60 and its 200-day simple moving average is $154.67.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The business had revenue of $617.00 million for the quarter. On average, equities analysts anticipate that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Masimo

In other news, Director William R. Jellison purchased 3,000 shares of the stock in a transaction dated Monday, August 11th. The shares were acquired at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the acquisition, the director owned 4,790 shares of the company's stock, valued at approximately $699,244.20. This represents a 167.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 9.70% of the company's stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Corporation (NASDAQ:MASI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.